-
公开(公告)号：US20060173632A1
公开(公告)日：2006-08-03
申请号：US11330137
申请日：2006-01-12
IPC分类号： G06F19/00
CPC分类号： C12Q1/485 , G01N33/57484 , G01N2800/52
摘要： A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of said comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.
摘要翻译： 描述了一种预测化疗有效性的方法。 该方法包括比较步骤和预测步骤。 比较步骤是将阈值与包含在从人类患者获得的肿瘤细胞的样品中包含的细胞周期蛋白依赖性激酶（CDK）的参数进行比较的步骤。 预测步骤是基于所述比较步骤的比较结果来预测有效性的步骤。 上述参数选自活性，表达水平以及活性与表达水平之比组成的组。
-
公开(公告)号：US07957910B2
公开(公告)日：2011-06-07
申请号：US11330137
申请日：2006-01-12
CPC分类号： C12Q1/485 , G01N33/57484 , G01N2800/52
摘要： A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of the comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.
摘要翻译： 描述了一种预测化疗有效性的方法。 该方法包括比较步骤和预测步骤。 比较步骤是将阈值与包含在从人类患者获得的肿瘤细胞的样品中包含的细胞周期蛋白依赖性激酶（CDK）的参数进行比较的步骤。 预测步骤是基于比较步骤的比较结果来预测有效性的步骤。 上述参数选自活性，表达水平以及活性与表达水平之比组成的组。
-
公开(公告)号：US08041514B2
公开(公告)日：2011-10-18
申请号：US11711053
申请日：2007-02-27
申请人： Satoshi Tanaka , Masaki Shibayama , Hideki Ishihara , Tomoko Matsushima , Aya Katayama , Yuko Kawasaki
发明人： Satoshi Tanaka , Masaki Shibayama , Hideki Ishihara , Tomoko Matsushima , Aya Katayama , Yuko Kawasaki
IPC分类号： G01N33/574 , G06F19/00
CPC分类号： G01N33/57415 , C12Q1/485 , G01N2333/4739 , G01N2333/9121 , G06F19/24
摘要： A method for judging feature of malignant tumor is described. The method comprises obtaining step, first comparing step, second comparing step and judging step. The obtaining step comprises obtaining a first parameter based on activity and expression level of a first cyclin dependent kinase (first CDK) contained in a tumor cell of the malignant tumor, a second parameter based on activity and expression level of a second cyclin dependent kinase (second CDK) contained in the tumor cell, a third parameter based on the first parameter and the second parameter, and a fourth parameter based on expression level of a cyclin contained in the tumor cell. The first comparing step comprises comparing a first threshold value with the third parameter. The second comparing comprises comparing a second threshold value with the fourth parameter. The judging step comprises judging the feature of the malignant tumor based on the comparison results of the first comparing step and the second comparing step.
摘要翻译： 描述了判断恶性肿瘤特征的方法。 该方法包括获得步骤，第一比较步骤，第二比较步骤和判断步骤。 获得步骤包括基于包含在恶性肿瘤的肿瘤细胞中的第一细胞周期依赖性激酶（第一CDK）的活性和表达水平获得第一参数，第二参数基于第二细胞周期蛋白依赖性激酶的活性和表达水平（ 第二CDK），基于第一参数和第二参数的第三参数，以及基于包含在肿瘤细胞中的细胞周期蛋白的表达水平的第四参数。 第一比较步骤包括将第一阈值与第三参数进行比较。 第二比较包括将第二阈值与第四参数进行比较。 判断步骤包括基于第一比较步骤和第二比较步骤的比较结果判断恶性肿瘤的特征。
-
4.发明授权Method of assessing properties of mammalian cells, and method of diagnosing cancer using the same 有权评估哺乳动物细胞特性的方法，以及使用该方法诊断癌症的方法公开(公告)号：US08921057B2
公开(公告)日：2014-12-30
申请号：US11597414
申请日：2005-05-30
IPC分类号： G01N33/574 , C12Q1/48 , G01N33/50
CPC分类号： C12Q1/485 , G01N33/5011 , G01N33/574
摘要： A CDK profile including a ratio of specific activities of two cyclin dependent kinases closely correlates with the malignancy grade and the presence/absence of the sensitivity to an irritant such as an anticancer agent of a cancer tissue in clinical medicine. Therefore, the properties of a mammalian cell, such as malignancy grade, proliferation potency, sensitivity to an irritant such as an anticancer agent can be assessed based on its CDK profile or by comparing the result of a specific activity ratio of two CDKs with a predetermined threshold corresponding to the ratio. This sensitivity assessing method shows a high ratio of correct assessing results particularly in positive or sensitivity and is useful in predicting efficacy of chemotherapy using the anticancer agent.
摘要翻译： 包括两种细胞周期蛋白依赖性激酶的比活性比例的CDK谱与恶性程度密切相关，以及对临床医学中癌症组织的抗癌剂等刺激物的敏感性的存在/不存在。 因此，哺乳动物细胞的性质，例如恶性程度，增殖效能，对刺激物如抗癌剂的敏感性可以基于其CDK分布或通过将两种CDK的比活性比与预定的 阈值对应于该比例。 这种敏感性评估方法显示出正确评估结果的高比例，特别是阳性或敏感性，并且可用于预测使用抗癌剂的化疗的功效。
-
5.发明授权公开(公告)号：US07682785B2
公开(公告)日：2010-03-23
申请号：US11474981
申请日：2006-06-27
IPC分类号： C12Q1/70
CPC分类号： G01N33/5011 , C12Q1/48 , G01N2800/52
摘要： The present invention provides a method for predicting an effectiveness of chemotherapy using an anticancer agent with high probability. The effectiveness is predicted based on a comparison of a parameter relating to CDK and/or CDK inhibitor in a tumor cell specimen obtained from a patient, with a corresponding threshold value to the parameter. The patient to be subjected this sensitivity prediction test of an anticancer agent is administered with the anticancer agent prior to removal of the tumor cell. The threshold is predetermined based on data of correlation between the selected parameter and anticancer agent therapy results obtained from a number of patients actually performed the therapy. Accordingly, the predicting method can provide information useful for determining whether to perform the chemotherapy to individual patients.
摘要翻译： 本发明提供了一种以高概率预测使用抗癌剂的化疗效果的方法。 基于从患者获得的肿瘤细胞样本中与CDK和/或CDK抑制剂相关的参数与参数的相应阈值进行比较来预测有效性。 抗癌剂的敏感性预测试验的患者在除去肿瘤细胞之前与抗癌剂一起施用。 基于从实际进行治疗的多个患者获得的所选参数和抗癌剂治疗结果之间的相关性的数据来预先设定阈值。 因此，预测方法可以提供用于确定是否对个体患者进行化学疗法的信息。
-
6.发明申请Method of Assessing Properties of Mammalian Cells, and Method of Diagnosing Cancer Using the Same 有权评估哺乳动物细胞性质的方法，以及使用该方法诊断癌症的方法公开(公告)号：US20070231837A1
公开(公告)日：2007-10-04
申请号：US11597414
申请日：2005-05-30
IPC分类号： G01N33/53
CPC分类号： C12Q1/485 , G01N33/5011 , G01N33/574
摘要： A CDK profile including a ratio of specific activities of two cyclin dependent kinases closely correlates with the malignancy grade and the presence/absence of the sensitivity to an irritant such as an anticancer agent of a cancer tissue in clinical medicine. Therefore, the properties of a mammalian cell, such as malignancy grade, proliferation potency, sensitivity to an irritant such as an anticancer agent can be assessed based on its CDK profile or by comparing the result of a specific activity ratio of two CDKs with a predetermined threshold corresponding to the ratio. This sensitivity assessing method shows a high ratio of correct assessing results particularly in positive or sensitivity and is useful in predicting efficacy of chemotherapy using the anticancer agent.
摘要翻译： 包括两种细胞周期蛋白依赖性激酶的比活性比例的CDK谱与恶性程度密切相关，以及对临床医学中癌症组织的抗癌剂等刺激物的敏感性的存在/不存在。 因此，哺乳动物细胞的性质，例如恶性程度，增殖效能，对刺激物如抗癌剂的敏感性可以基于其CDK分布或通过将两种CDK的比活性比与预定的 阈值对应于该比例。 这种敏感性评估方法显示出正确评估结果的高比例，特别是阳性或敏感性，并且可用于预测使用抗癌剂的化疗的功效。
-
公开(公告)号：US20070202555A1
公开(公告)日：2007-08-30
申请号：US11711053
申请日：2007-02-27
申请人： Satoshi Tanaka , Masaki Shibayama , Hideki Ishihara , Tomoko Matsushima , Aya Katayama , Yuko Kawasaki
发明人： Satoshi Tanaka , Masaki Shibayama , Hideki Ishihara , Tomoko Matsushima , Aya Katayama , Yuko Kawasaki
IPC分类号： G01N33/574 , G06F19/00
CPC分类号： G01N33/57415 , C12Q1/485 , G01N2333/4739 , G01N2333/9121 , G06F19/24
摘要： A method for judging feature of malignant tumor is described. The method comprises obtaining step, first comparing step, second comparing step and judging step. The obtaining step comprises obtaining a first parameter based on activity and expression level of a first cyclin dependent kinase (first CDK) contained in a tumor cell of the malignant tumor, a second parameter based on activity and expression level of a second cyclin dependent kinase (second CDK) contained in the tumor cell, a third parameter based on the first parameter and the second parameter, and a fourth parameter based on expression level of a cyclin contained in the tumor cell. The first comparing step comprises comparing a first threshold value with the third parameter. The second comparing comprises comparing a second threshold value with the fourth parameter. The judging step comprises judging the feature of the malignant tumor based on the comparison results of the first comparing step and the second comparing step.
摘要翻译： 描述了判断恶性肿瘤特征的方法。 该方法包括获得步骤，第一比较步骤，第二比较步骤和判断步骤。 获得步骤包括基于包含在恶性肿瘤的肿瘤细胞中的第一细胞周期蛋白依赖性激酶（第一CDK）的活性和表达水平获得第一参数，第二参数基于第二细胞周期蛋白依赖性激酶的活性和表达水平（ 第二CDK），基于第一参数和第二参数的第三参数，以及基于包含在肿瘤细胞中的细胞周期蛋白的表达水平的第四参数。 第一比较步骤包括将第一阈值与第三参数进行比较。 第二比较包括将第二阈值与第四参数进行比较。 判断步骤包括基于第一比较步骤和第二比较步骤的比较结果判断恶性肿瘤的特征。
-
8.发明申请公开(公告)号：US20070003964A1
公开(公告)日：2007-01-04
申请号：US11474981
申请日：2006-06-27
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/5011 , C12Q1/48 , G01N2800/52
摘要： The present invention provides a method for predicting an effectiveness of chemotherapy using an anticancer agent with high probability. The effectiveness is predicted based on a comparison of a parameter relating to CDK and/or CDK inhibitor in a tumor cell specimen obtained from a patient, with a corresponding threshold value to the parameter. The patient to be subjected this sensitivity prediction test of an anticancer agent is administered with the anticancer agent prior to removal of the tumor cell. The threshold is predetermined based on data of correlation between the selected parameter and anticancer agent therapy results obtained from a number of patients actually performed the therapy. Accordingly, the predicting method can provide information useful for determining whether to perform the chemotherapy to individual patients.
摘要翻译： 本发明提供了一种以高概率预测使用抗癌剂的化疗效果的方法。 基于从患者获得的肿瘤细胞样本中与CDK和/或CDK抑制剂相关的参数与参数的相应阈值进行比较来预测有效性。 抗癌剂的敏感性预测试验的患者在除去肿瘤细胞之前与抗癌剂一起施用。 基于从实际进行治疗的多个患者获得的所选参数和抗癌剂治疗结果之间的相关性的数据来预先设定阈值。 因此，预测方法可以提供用于确定是否对个体患者进行化学疗法的信息。
-
9.发明授权Diagnosis support system for cancer, diagnosis support information providing method for cancer, and computer program product 有权癌症诊断支持系统，癌症诊断支持信息提供方法和计算机程序产品公开(公告)号：US08921114B2
公开(公告)日：2014-12-30
申请号：US12197714
申请日：2008-08-25
摘要： A diagnosis support system for cancer is disclosed that comprises: a measurement value acquiring section for acquiring a measurement value of a first cancer patient; a sample data memory for storing sample data of a plurality of cancer patients different from the first patient; a reference range determination section for determining a reference range based on the measurement value of the first cancer patient; a display unit; and a display controller for controlling the display unit to display a diagnosis support screen showing the clinical information included in the sample data having measurement value within the reference range. A method of providing cancer diagnosis support information and a computer program product are also disclosed.
摘要翻译： 公开了一种用于癌症的诊断支持系统，包括：测量值获取部分，用于获取第一癌症患者的测量值; 用于存储与第一患者不同的多个癌症患者的样本数据的样本数据存储器; 参考范围确定部分，用于基于第一癌症患者的测量值来确定参考范围; 显示单元; 以及显示控制器，用于控制显示单元显示诊断支持屏幕，其显示包含在具有参考范围内的测量值的样本数据中的临床信息。 还公开了提供癌症诊断支持信息的方法和计算机程序产品。
-
公开(公告)号：US20050131057A1
公开(公告)日：2005-06-16
申请号：US10926409
申请日：2004-08-25
申请人： Naoto Ueno , Hideki Ishihara , Tamotsu Sudo , Tomoko Matsushima
发明人： Naoto Ueno , Hideki Ishihara , Tamotsu Sudo , Tomoko Matsushima
IPC分类号： A61K31/337 , C12Q1/68 , G01N33/574
CPC分类号： A61K31/337 , C12Q1/6886 , C12Q2600/158
摘要： The present invention provides a method for determining the chemosensitivity of a cancer cell to a taxane comprising assessing the effect of the taxane on the expression level or activity of one or more cell cycle molecules in a cancer cell. Such a method makes use of an automated analyzer system wherein cell cycle parameters (molecules) such as CDK1 kinase activity, CDK1 expression, CDK2 kinase activity, CDK2 expression, MAD2 expression, Cyclin B1, Cyclin E expression, p21 expression, and CDK6 expression; are assessed. The present invention further provides a method of obtaining a cell cycle profile of a cancer cell that is sensitive to a taxane.
摘要翻译： 本发明提供了确定癌细胞对紫杉烷的化学敏感性的方法，包括评估紫杉烷对癌细胞中一种或多种细胞周期分子的表达水平或活性的影响。 这种方法利用自动分析系统，其中诸如CDK1激酶活性，CDK1表达，CDK2激酶活性，CDK2表达，MAD2表达，细胞周期蛋白B1，细胞周期蛋白E表达，p21表达和CDK6表达的细胞周期参数（分子） 被评估。 本发明还提供了获得对紫杉烷敏感的癌细胞的细胞周期特征的方法。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.032 秒)
